Stay updated on Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.

Latest updates to the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page
- CheckyesterdayChange DetectedThe page no longer displays Type 2 diabetes and the MedlinePlus Genetics related topics section. This reduces disease-specific context and associated background resources.SummaryDifference0.2%

- Check8 days agoChange DetectedThe page adds new related topics, including Type 2 diabetes and a MedlinePlus Genetics entry. The revision label updates from v3.6.5 to v3.6.6 to reflect a new version.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRemoved the related topics entries for Type 2 diabetes and MedlinePlus Genetics from the page. This change affects discoverability but not the core study details.SummaryDifference0.2%

- Check29 days agoChange DetectedThe page revision label changed from v3.6.4 to v3.6.5, indicating a software update. No trial details or visible content were altered.SummaryDifference0.1%

- Check37 days agoChange DetectedThere are no additions or deletions to report. The page content appears unchanged with respect to the study details and related sections.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page revision line was updated from v3.6.3 to v3.6.4. This indicates a minor update to the page's version metadata rather than to the study details.SummaryDifference0.1%

Stay in the know with updates to Dapagliflozin Impact on T2DM Risk Factors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin Impact on T2DM Risk Factors Clinical Trial page.